566169-93-5

Basic information

• Product Name: 6-OH-BTA-1
• Synonyms: 2-[4''-(Methylamino)phenyl]-6-hydroxybenzothiazole;6-Benzothiazolol, 2-[4-(methylamino)phenyl]-;6-OH-BTA-1;6-Benzothiazolol, 2-[4-(methylamino)phenyl]-hydrochloride;6-OH-BTA-1 (free base);2-(4-(Methylamino)phenyl)benzo[d]thiazol-6-ol
• CAS NO: 566169-93-5
• Molecular Formula: C₁₄H₁₂N₂OS
• Molecular Weight: 256.32288
• Mol File: 566169-93-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 475.7±51.0 °C(Predicted)
• Appearance: /
• Density: 1.353±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.74±0.40(Predicted)
• CAS DataBase Reference: 6-OH-BTA-1(CAS DataBase Reference)
• NIST Chemistry Reference: 6-OH-BTA-1(566169-93-5)
• EPA Substance Registry System: 6-OH-BTA-1(566169-93-5)

Safety Data

• Hazardous Substances Data: 566169-93-5(Hazardous Substances Data)

Usage

Chemical Properties

Yellow solid

Upstream product

• 89415-43-0 (4-aminophenyl)boronic acid 
• 2941-58-4 2-bromo-6-methoxy-1,3 benzothiazole 
• 62-23-7 4-nitro-benzoic acid 
• 73702-95-1 N-(4-methoxyphenyl)-4-nitrothiobenzamide 
• 43036-14-2 6-methoxy-2-(4-nitrophenyl)benzothiazole 
• 122-04-3 4-nitro-benzoyl chloride 
• 104-94-9 4-methoxy-aniline 
• 24730-11-8 N-(4-methoxyphenyl)-4-nitrobenzamide 
• 43036-17-5 2-(4-aminophenyl)-6-methoxybenzothiazole 
• 1071832-31-9 C₁₆H₁₆N₂OS 
• 6274-29-9 2-amino-5-methoxy-thiophenol 
• 1747-60-0 6-methoxybenzothiazol-2-ylamine 
• 401813-34-1 4-(6-methoxybenzo[d]thiazol-2-yl)-N-methylaniline 

Downstream Products

• 1071423-43-2 2-(4'-(methylamino)phenyl)-6-fluoroethoxybenzothiazole 
• 1301256-39-2 2-(4-(N-methyl-N-tert-butoxycarbonylamino)phenyl)benzo[d]thiazol-6-ol 

Relevant articles and documents

TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM

Disclosed are bispecific compounds (degraders) that target α-synuclein protein for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat neurodegenerative diseases.

(3-FLUORO-2-HYDROXY)PROPYL-FUNCTIONALIZED ARYL DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR THE DIAGNOSIS OR TREATMENT OF NEURODEGENERATIVE BRA

The present invention relates to (3-fluoro-2-hydroxy)propyl-functionalized aryl derivatives or to the pharmaceutically acceptable salt thereof, to a method for preparing same, and to a pharmaceutical composition containing same as active ingredients for t

Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

The synthesis and evaluation of a series of neutral analogues of thioflavin-T (termed BTA's) with high affinities for aggregated amyloid and a wide range of lipophilicities are reported. Radiolabeling with high specific activity [(11)C]methyl iodide provided derivatives for in vivo evaluation. Brain entry in control mice and baboons was high for nearly all of the analogues at early times after injection, but the clearance rate of radioactivity from brain tissue varied by more than 1 order of magnitude. Upon the basis of its rapid clearance from normal mouse and baboon brain tissues, [N-methyl-(11)C]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (or [(11)C]6-OH-BTA-1) was selected as the lead compound for further evaluation. The radiolabeled metabolites of [(11)C]6-OH-BTA-1 were polar and did not enter brain. The binding affinities of [N-methyl-(3)H]6-OH-BTA-1 for homogenates of postmortem AD frontal cortex and synthetic Abeta(1-40) fibrils were similar (K(d) = 1.4 nM and 4.7 nM, respectively), but the ligand-to-Abeta peptide binding stoichiometry was approximately 400-fold higher for AD brain than Abeta(1-40) fibrils. Staining of AD frontal cortex tissue sections with 6-OH-BTA-1 indicated the selective binding of the compound to amyloid plaques and cerebrovascular amyloid. The encouraging in vitro and in vivo properties of [(11)C]6-OH-BTA-1 support the choice of this derivative for further evaluation in human subject studies of brain Abeta deposition.